ArticleJOR spine2025
Lovastatin-Loaded Nanoparticles in a Thermosensitive Chitosan Hydrogel as a Sustained Release System for Treating Intervertebral Disc Degeneration: In Vitro Cell Culture Study and In Vivo Evaluation Using a Needle-Puncture Induced Degeneration Model in Rat Caudal Discs.
Article in JOR spine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Sustained release of therapeutic factors, such as lovastatin, is theoretically more beneficial than a single injection in promoting anabolic stimulation to nucleus pulposus cells/tissues. This study aimed to develop lovastatin-loaded nanoparticles (LVS-NPs) incorporated into thermosensitive chitosan/gelatin/glycerophosphate (C/G/GP) hydrogel for the treatment of intervertebral disc (IVD) degeneration. Methods: LVS-NPs were prepared using an oil-in-water emulsion evaporation method, followed by characterization and drug encapsulation efficiency. LVS-NPs were then incorporated into C/G/GP hydrogel for controlled drug release, with subsequent in vitro and in vivo evaluations. Results: LVS-NPs showed a round shape with a mid-range polydispersity index, which shall benefit lovastatin release. Rheological study showed incorporation of LVS-NPs into hydrogel does not change thermal gelation property. Drug release tests demonstrated that lovastatin was released steadily from the hydrogel containing LVS-NPs over 7 days. The LVS-NPs-containing hydrogel demonstrated good biocompatibility and low cytotoxicity in the in vitro studies including WST-8 assay, LDH assay, TUNEL test and Western blot. Analysis of hydrogels containing LVS-NPs on human nucleus pulposus cells revealed enhanced production of aggrecan and Type II collagen without inducing apoptosis, though higher concentrations or longer treatment durations may be required to achieve effects comparable to those of 5 μM lovastatin. In the animal study, various treatment regimens were applied to a rat caudal disc model mimicking early-stage IVD degeneration. Despite lovastatin or LVS-NPs in hydrogel, significant decreases in disc height index and extensive degeneration observed through MRI and histological staining indicated a complete loss of nucleus pulposus tissue in all hydrogel-treated groups, likely due to mechanical compression from the injected hydrogel within the confined space of the annulus fibrosus, which needs further investigation. Conclusions: LVS-NPs demonstrated sustained release of lovastatin and extended stimulatory effects on human nucleus pulposus cells in vitro. However, further research is needed to optimize the hydrogel volume and its ratio to intradiscal space and increase lovastatin concentration within LVS-NPs to achieve optimal therapeutic outcomes while minimizing mechanical compression to surrounding tissues.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.